120例贝伐单抗联合化疗治疗实体肿瘤的临床研究

Clinical Study of 120 Cases With Bevacizumab Combine With Chemotherapy in Treatment of Solid Tumors

目的探讨贝伐单抗联合化疗治疗实体肿瘤的临床研究。方法选取我院收治的120例晚期实体肿瘤患者,随机分为两组,每组60例。对照组采取常规治疗,观察组采用贝伐单抗联合化疗。治疗3个疗程后比较两组患者的治疗效果。结果观察组的CR、PR以及PD均优于对照组,P<0.05,差异具有统计学意义。结论贝伐单抗联合化疗治疗结直肠癌、乳腺癌等实体肿瘤治疗效果较好。

Objective To evaluate clinical studies of bevacizumab combined with chemotherapy in the treatment of solid tumors. Methods Selected 120 cases of patients with advanced solid tumors in our hospital, were randomly divided into two groups, each group had 60 cases. The control group received conventional treatment, the observation group bevacizumab in combination with chemotherapy. After three courses of therapy treatment two groups were compared. Results The observation group of patients with CR, PR and PD were better than the control group,P〈0.05, had difference statistically significance.Conclusion The treatment of solid tumors, bevacizumab combined with chemotherapy in colorectal cancer, breast cancer is better.